SillaJen Biotherapeutics is located in San Francisco, one of the largest and most innovative biotech clusters in the world. SillaJen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials.
* A tumor with green patches of vaccinia virus infection surrounded by red blood vessels. Image courtesy of McDonald Lab
Cancer-Killing Virus Acts by Alerting Immune System
A collaboration between SillaJen Biotherapeutics researchers and the McDonald Lab at the University of California San Francisco highlights the potential for combination therapy using oncolytic viruses and immunotherapy.
Combination trials with Pexa-Vec and immune checkpoint inhibitors
· First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) NCT03071094